NASDAQ:GENE - Genetic Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.83 -0.02 (-2.35 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$0.85
Today's Range$0.82 - $0.87
52-Week Range$0.51 - $2.04
Volume14,900 shs
Average Volume30,003 shs
Market Capitalization$13.48 million
P/E RatioN/A
Dividend YieldN/A
Beta3.97
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Receive GENE News and Ratings via Email

Sign-up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GENE
CUSIPN/A
Phone61-3-8412-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$140,000.00
Book Value$0.22 per share

Profitability

Miscellaneous

Employees16
Market Cap$13.48 million
OptionableOptionable

Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Has Genetic Technologies been receiving favorable news coverage?

Media headlines about GENE stock have been trending somewhat positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genetic Technologies earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are some of Genetic Technologies' key competitors?

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the folowing people:
  • Dr. Paul Alexander Kasian Ph.D., Exec. Chairman & CEO (Age 62)
  • Dr. Richard Allman, Scientific Director (Age 59)
  • Dr. Jerzy Muchnicki, Exec. Director & Bus. Devel. Director
  • Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, COO, CFO & Company Sec.

How do I buy shares of Genetic Technologies?

Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $0.83.

How big of a company is Genetic Technologies?

Genetic Technologies has a market capitalization of $13.48 million and generates $140,000.00 in revenue each year. Genetic Technologies employs 16 workers across the globe.

What is Genetic Technologies' official website?

The official website for Genetic Technologies is http://www.gtglabs.com.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 61-3-8412-7000 or via email at [email protected]


MarketBeat Community Rating for Genetic Technologies (NASDAQ GENE)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote "Outperform" if you believe GENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Liquidity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel